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eNTRODUCTION: THE NICHE CONCEPT
Key aspects of adult stem cell biology include not
ust identifying multipotent cells, but also determining
hese cells’ physical location within the organism it-
elf, the entity referred to as the stem cell “niche.”
choﬁeld ﬁrst proposed the concept of a hematopoi-
tic stem cell (HSC) niche in 1978, suggesting that
tem cells are ﬁxed tissue cells located within a deﬁned
icroenvironment and function to regulate prolifera-
ion and differentiation of the HSC [1]. Work by
any groups since then has shown that the supporting
stromal” cells, in addition to providing a tether for
tem cells, play a key role in helping maintain the stem
ell population by providing paracrine signals that
rovide the checks and balances of self-renewal, dif-
erentiation, and mobilization.
STEOBLASTIC AND VASCULAR BONE MARROW
ICHES
It has been established that rather than being ran-
omly distributed throughout the bone marrow (BM)
avity, HSCs are more speciﬁcally localized to the
nner surface (endosteum) of the trabecular area of
one and around blood vessels. Within the endosteal
iche, the speciﬁc cell type most closely associated
ith HSCs is the osteoblast.
Osteoblasts are normally involved in osteogenesis,
orking in opposition to osteoclasts, which are in-
olved in the resorption of bone. A transgenic mouse
odel in which osteoblasts are speciﬁcally ablated
auses a depletion of murine HSCs in vivo. Con-
ersely, increasing the number of osteoblasts increases
he number of HSCs; in this setting, the numbers of
ature myeloid and lymphoid cells do not seem to
ncrease, suggesting that the pathways that control
SC differentiation prevent inappropriate hemato- ooiesis even in the face of increasing numbers of
SCs.
Osteoblasts are an extremely rich source of cyto-
ines, providing one mechanism by which they affect
SC survival. However, these cytokines are not suf-
cient to ensure HSC survival in vitro, demonstrating
hat the microenvironment provides other factors, in-
luding extracellular matrix (ECM) proteins and in-
ercellular signalling pathways, necessary to support
SC survival in vivo.
In recent years, another niche for HSCs within the
M cavity has been identiﬁed and studied: the BM
asculature. Unlike the osteoblastic niche, which is
hought to be largely concerned with self-renewal, the
ascular niche appears to regulate differentiation of
tem and progenitor cells, as well as the ingress and
gress of circulating hematopoietic cells [2].
The hematopoietic and vascular systems are
losely related developmentally, being derived from a
ingle common precursor, the hemangioblast. Vascu-
ar precursor cells are required for the development of
lood islands in the yolk sac. At day 35 of embryonic
ife, human CD34 cells can be found in the wall of
he aorta. Understanding the vascular architecture of
he BM provides further insight into the functional
ntimacy of endothelium and hematopoietic cells that
xtends into postnatal life. After entering the marrow,
rteries divide into arterioles and capillaries, ulti-
ately ending in sinusoids distributed around a cen-
ral sinus. The sinusoids consist of a single layer of
ndothelium and lack the normal supporting stromal
ells that surround blood vessels found in other or-
ans. In fact, the supporting perivascular tissue com-
rises mainly of hematopoietic cells. The absence of a
omplex vascular wall explains the high level of per-
eability seen in BM endothelium. Similar sinusoidal
ndothelium is found in the spleen and liver, 2 other
rgans involved in hematopoiesis.
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A. R. Cuddihy and G. M. Crooks44The vascular niche is also the gateway into the
eripheral blood circulation for HSC, progenitors,
nd fully differentiated blood cells. Owing to the
ack of supporting stroma and pericyte coverage,
ome cells, such as megakaryocytes, appear to be
ble to transmigrate through the cytoplasm of a
ingle endothelial cell (EC) to enter the circulation.
ther cells may enter the circulation in this fashion
r through fenestrations between individual ECs.
onversely, and perhaps more importantly within
he auspices of BM transplantation (BMT), circu-
ating donor HSCs and hematopoietic progenitor
ells (HPCs) can enter the BM through the vascu-
ature, engraft in the host marrow, and establish de
ovo hematopoiesis after transplantation. Several
xcellent reviews describe this process in more de-
ail and provide speciﬁc references [2-4].
Many questions surround the role of the vascular
iche in regulation of hematopoiesis and engraftment
nd, conversely, the role of BM-derived cells in endo-
helial differentiation and angiogenesis. If, under nor-
al conditions, HSCs and HPCs, as well as fully
ature myeloid and erythroid cells, are able to enter
nd exit the circulation relatively freely, why then is
ngraftment largely unsuccessful without some form
f conditioning therapy? Do different conditioning
egimens make the BM endothelium be more permis-
ive to homing, extravasation, and engraftment of do-
or HSCs? What is the mechanism by which BM
rovides the pool of circulating endothelial progeni-
ors that in turn contribute to the vasculature of other
rgans during steady state, tissue remodeling, and
umor angiogenesis? Studies into the endothelial bi-
logy of the BM provide essential information on the
rocesses of engraftment and hematopoiesis and have
ide implications for future developments in HSC
herapy.
ASCULAR ENDOTHELIAL GROWTH FACTOR
ND ANGIOGENESIS
Vascular endothelial growth factor (VEGF)-A, a
ritical mediator of vascular growth and differentia-
ion, is one of a family of vascular growth factors that
lso includes VEGF-B, VEGF-C, VEGF-D, and pla-
ental growth factor (PlGF). The members of the
EGF family are key regulators of EC migration,
urvival, and cellular proliferation. VEGF acts as a
itogen for ECs that express its receptor (VEGF-R2)
nd causes formation of new capillaries and sprouting
r branching in blood vessels. VEGF is required for
ngiogenesis during normal organ development in the
mbryo. Deletion of a single VEGF allele is embry-
nically lethal, and deletion of VEGF-R2 leads to
efects in organ angiogenesis [5]. Dr. Donald
cDonald’s laboratory at the University of Califor- tia, San Francisco has been investigating the VEGF’s
ole in ECs and in angiogenesis in both normal and
umor cells. His group was among the ﬁrst to charac-
erize the age-related dependency of ECs on VEGF.
VEGF-responsive vessels typically demonstrate
ense branching of capillary networks, and their en-
othelium is fenestrated and more permeable to mac-
omolecules. The loss of VEGF dependency is asso-
iated with increased pericyte coverage and decreased
ranching, fenestrations, and permeability. Baffert
t al. [6] found that VEGF dependency does not
ersist throughout postnatal life. During develop-
ent, as blood vessels become less responsive to
EGF, another growth factor, angiopoietin-1
Ang-1), takes over vascular remodeling, increasing
lood vessel diameter and decreasing EC fenestrations
7]. The receptor for Ang-1 is Tie-2, a receptor tyrosine
inase expressed on both ECs and HSCs [8].
VEGF inhibition causes an increase in EC apo-
tosis in mouse tracheal mucosa, regression of blood
essels, and a decrease in VEGF receptor expression
9,10]. The McDonald group was able to demonstrate
hat VEGF inhibitors cause similar effects in the vas-
ulature of tumors, including decreased fenestrations
nd overall decreased extravasation of macromolecules
11,12].
NTERACTIONS OF BONE MARROW ENDOTHELIAL
ELLS AND HEMATOPOIESIS
Recent work by Raﬁi and others has provided
ome unique insight into the role of the BM vascula-
ure in the regulation of hematopoiesis and control of
he movement of hematopoietic cells in and out of the
arrow. The isolation and characterization of BM
Cs (BMECs) has made it possible to elucidate in
itro how BMECs and HSCs regulate and respond to
ach other. BMECs can support proliferation and
ifferentiation of multipotent CD34 cells in vitro,
nd direct contact enhances survival of HPCs [13].
hese studies have also revealed that BM endothelium
egulates HSC differentiation and mobilization, and
lso that mobilized HSCs themselves are able to act
irectly on BMECs. More recently, Kiel et al. [14]
ere able to use the signaling lymphocytic activation
olecule family of cell surface markers to determine
hat HSCs themselves are directly associated with the
inusoidal endothelium in BM and spleen in vivo. This
vidence supports a role for the endothelium in reg-
lating various aspects of HSC maintenance and dif-
erentiation [14].
Monolayers of BMECs have also been used to
uild models for the migration of circulating HSCs
nto the BM, demonstrating that homing of cord
lood CD34 cells and their subsequent transendo-
helial migration through a BMEC monolayer de-
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Endothelial Biology and the Bone Marrow 45ends on a chemokine gradient from stromal cell–
erived factor and on the expression of E-selectin on
MECs [15].
Interestingly, Raﬁi’s group and others have shown
hat HSCs themselves, as well as more mature pro-
enitor cells, such as mast cells, express VEGF and its
eceptor VEGF-R2, thus allowing an autocrine loop
o support cell survival [16,17]. In the case of more
ature progenitor cells, VEGF expression is itself
riven by cytokines such as kit ligand and interleukin
IL)-3. VEGF in turn acts on the BMECs to induce
hanges in the EC layer, including an increase in
enestrations. This in turn facilitates transendothelial
igration of progenitor cells into the sinusoidal lu-
en [18], from where cells then migrate to sites of
ngiogenesis and/or wound healing.
These studies beg the question of how endothe-
ium is affected by the various conditioning regimens
sed in BMT. The tissue damage caused by irradia-
ion or cytotoxic agents may mobilize HSCs from the
steoblastic niche to the vascular niche mediated by
ytokines released in response to cellular stress. A
ecent article has described the role of radiation in
nhancing mobilization of hematopoietic and endo-
helial progenitors from the BM through an matrix
etalloproteinase-9–dependent mechanism that also
nvolves VEGF and kit ligand [19]. It is perhaps pos-
ible that the increased fenestrations induced by mo-
ilized endogenous HSCs may also make the BM
ore permissive for engraftment.
NTEGRINS, ENDOTHELIAL CELL PROLIFERATION,
ND PROGENITOR CELL HOMING
Another important interaction between endothe-
ium and HSC is the regulation of homing of circu-
ating HSCs and HPCs to target tissues and organs.
lues to better understanding the process of homing
o BM endothelium may come from studies on tumor-
nduced angiogenesis.
Integrins are a family of heterodimeric cell sur-
ace–expressed proteins consisting of  and  sub-
nits in various combinations. These subunits play a
ey role in facilitating the ability of migrating cells
o attach to ligands found on the ECM. The bind-
ng of integrins to their ligands triggers signaling
athways that inhibit apoptotic pathways and thus
romote cell survival and proliferation [20].
Varner’s group at the University of California, San
iego has studied the role of integrins in neovascu-
arization during angiogenesis in tumors. Zhong et al.
21] ﬁrst characterized the role of the ECM protein
el-1 in neovascularization. Del-1 was known to pro-
ote extracellular migration and angiogenesis in co-
peration with the integrin v3, but the biological
echanisms were unclear. Using ischemic animal oodels in which puriﬁed Del-1 or a plasmid encoding
el-1 had been injected into the ischemic limb, these
uthors observed that Del-1 initially bound to another
ntegrin, v5, causing the transcriptional activation
f several genes, including cyclin D1, Hox3, and
v3, which promotes extracellular proliferation and
ubsequent new vessel growth [21].
Dr. Varner’s laboratory has extensively studied
he role of 41 (previously known as VLA-4) in
eovascularization. Her group has shown that 41
s expressed in proliferating ECs rather than in
uiescent ECs. During this proliferation period,
41 mediates a critical interaction with its ligand,
ascular cell adhesion molecule (VCAM)-1, ex-
ressed on proliferating pericytes. In this way, for-
ation of the new vessel itself and the supporting
ericytes go hand in hand. Inhibiting either 41 or
CAM-1 through the use of speciﬁc antibodies
eads to apoptosis of both ECs and pericytes and to
ngiogenic failure [22,23].
The ability of myeloid cells and macrophages to
arget tumors appears to depend on their expression
f 41, which also promotes the ability of macro-
hages to invade the tumor space. Once in the
umor space, macrophages can express growth fac-
ors such as VEGF, which promote angiogenesis
23]. CD34 BM-derived progenitor cells also ex-
ress 41, which facilitates homing of HPCs to
CAM-1–expressing cells in actively remodeling
eovasculature. These progenitor cells can then dif-
erentiate into the ECs that make up the vasculature
24]. Interestingly, some recent studies have dem-
nstrated that integrins play a key role in homing of
SCs and HPCs to the BM from the circulation
25] and that VEGF inhibition down-regulates in-
egrin expression in ECs [26].
The complex processes by which progenitor cell
obilization, growth factor signaling, transendothe-
ial migration, homing, and maturation occur during
umor angiogenesis provides possible insight into how
ngraftment occurs after BMT and also how it may be
nhanced. For example, localized expression of VEGF
n the BM endothelium may increase fenestrations
hat allow HSC extravasation from the circulation into
he BM space. Engineering the expression of particu-
ar integrins and/or their ECM ligands may improve
oming of HSCs to the BM endothelium. Therefore,
t may be possible to take cues from the study of tumor
ngiogenesis and neovascularization and apply them
o BMT and HSC biology in general.
UMMARY
Until recently, the vascular niche of the BM has
eceived relatively little interest in the stem cell biol-
gy community. Although it is probably less impor-
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A. R. Cuddihy and G. M. Crooks46ant for stem cell renewal than the osteoblastic niche,
he vascular niche interacts with HSCs in other crit-
cal ways; it provides a tightly regulated gateway for
oth ingress from and egress to the circulation, and
lso may control stages of stem cell and progenitor
ifferentiation. The ﬁelds of vascular and tumor biol-
gy have revealed mechanisms for angiogenesis and
etastasis that can be used as a platform from which
o study mobilization and engraftment of HSCs. The
nteractions of HSCs and endothelium should be con-
idered in the design of more speciﬁc and targeted
onditioning regimens for BMT.
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